

QCDR and MIPS Measure Specifications

Measure ID	Measure Title	Measure Description	NQS Domain	Numerator	Denominator	Denominator Exclusions	Denominator Exceptions
IQSS1	Hypogonadism: Serum T, CBC, PSA, IPSS within 6 months of Rx	Percentage of patients with a new diagnosis of hypogonadism receiving androgen replacement therapy who have serum T, CBC, PSA, and IPSS documented within 6 months of first treatment	Effective Clinical Care	Serum T, CBC, PSA, and IPSS within 6 months of first treatment	Patients, regardless of age, with a new diagnosis of hypogonadism receiving first androgen replacement therapy	None	None
IQSS2	Prostate Cancer: Newly diagnosed with document T, PSA, Gleason	Percentage of newly diagnosed prostate cancer patients who prior to treatment have a documented evaluation of primary tumor (T) stage, PSA score, and Gleason score	Effective Clinical Care	All prostate cancer patients having a documented T stage, PSA score and Gleason score prior to treatment	All newly diagnosed prostate cancer patients, regardless of age	None	None
IQSS3	Prostate Cancer: Treatment Options Counseling	Newly diagnosed prostate cancer patients receiving definitive local treatment (surgery, radiation, cryotherapy) with documented counseling of all treatment options (active surveillance, surgery, radiation)	Communication and Care Coordination	All patients with a diagnosis or prostate cancer receiving definitive treatment and have received counseling	All patients, regardless of age, with a diagnosis or prostate cancer receiving definitive treatment	None	None
MUSIC11	Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months	Percentage of patients on active surveillance that have ≥ 2 tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	Effective Clinical Care	# of patients on active surveillance that have ≥ 2 tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	# of patients aged 30 or older with new diagnosis of low and low-intermediate prostate cancer (Gleason 6 or low volume Gleason 3+4)	Prostate cancer patients < 30 years of age; Patients that have had prior treatment for prostate cancer	None
IQSS4	BPH: Anticholinergics	Percentage of patients with BPH and treatment with anticholinergics where a PVR is performed	Effective Clinical Care	PVR performed within 6 months anticholinergic med start date (first anticholinergic med date after dx)	BPH patients, regardless of age, treated with anticholinergics	None	None
IQSS5	Counseling SUI	Percentage of patients undergoing surgery for SUI where treatment counseling was documented prior to surgery	Communication and Care Coordination	Counseling prior to surgery date	SUI patients, regardless of age, having a sling	None	None
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	Efficiency and Cost Reduction	Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer	All patients, regardless of age, with a diagnosis of prostate cancer and low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy	None	None
111	Pneumococcal Vaccination Status for Older Adults	Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.	Community/ Population Health	Patients who have ever received a pneumococcal vaccination	Patients 65 years of age and older with a visit during the measurement period	Exclude patients who were in hospice care during the measurement year	None
113	Colorectal Cancer Screening	Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.	Effective Clinical Care	Patients with one or more screenings for colorectal cancer	Patients 50-75 years of age with a visit during the measurement period	Patients with a diagnosis or past history of total colectomy or colorectal cancer. Exclude patients who were in hospice care during the measurement year.	None
119	Diabetes: Medical Attention for Nephropathy	The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.	Effective Clinical Care	Patients with a screening for nephropathy or evidence of nephropathy during the measurement period	Patients 18-75 years of age with diabetes with a visit during the measurement period	Exclude patients who were in hospice care during the measurement year	None
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter Normal Parameters: Age 18 years and older BMI => 18.5 and < 25 kg/m2	Community/ Population Health	Patients with a documented BMI during the encounter or during the previous twelve months, AND when the BMI is outside of normal parameters, a follow-up plan is documented during the encounter or during the previous twelve months of the current encounter	All patients 18 and older on the date of the encounter with at least one eligible encounter during the measurement period	Patients who are pregnant Patients receiving palliative care Patients who refuse measurement of height and/or weight or refuse follow-up	Patients with a documented Medical Reason: * Elderly Patients (65 or older) for whom weight reduction/weight gain would complicate other underlying health conditions such as the following examples: *Illness or physical disability *Nutritional deficiency, such as Vitamin/mineral deficiency *Mental illness, dementia, confusion * Patients in an urgent or emergent medical situation where time is of the essence and to delay treatment would jeopardize the patient's health status

QCDR and MIPS Measure Specifications

Measure ID	Measure Title	Measure Description	NQS Domain	Numerator	Denominator	Denominator Exclusions	Denominator Exceptions
130	Documentation of Current Medications in the Medical Record	Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration.	Patient Safety	Eligible professional or eligible clinician attests to documenting, updating or reviewing the patient's current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosages, frequency and route of administration	All visits occurring during the 12 month measurement period for patients aged 18 years and older	None	Medical Reason: Patient is in an urgent or emergent medical situation where time is of the essence and to delay treatment would jeopardize the patient's health status
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period.	Effective Clinical Care	Patients who had an active medication of aspirin or another antiplatelet during the measurement year	Patients 18 years of age and older with a visit during the measurement period who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD overlapping the measurement year	Patients who had documentation of use of anticoagulant medications overlapping the measurement year Exclude patients who were in hospice care during the measurement year	None
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	Community/Population Health	Population 1: Patients who were screened for tobacco use at least once within 24 months Population 2: Patients who received tobacco cessation intervention Population 3: Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation intervention if identified as a tobacco user	Population 1: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period Population 2: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period who were screened for tobacco use and identified as a tobacco user Population 3: All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period	None	Population 1: Documentation of medical reason(s) for not screening for tobacco use (eg, limited life expectancy, other medical reason) Population 2: Documentation of medical reason(s) for not providing tobacco cessation intervention (eg, limited life expectancy, other medical reason) Population 3: Documentation of medical reason(s) for not screening for tobacco use OR for not providing tobacco cessation intervention for patients identified as tobacco users (eg, limited life expectancy, other medical reason)
236	Controlling High Blood Pressure	Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period	Effective Clinical Care	Patients whose blood pressure at the most recent visit is adequately controlled (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) during the measurement period	Patients 18-85 years of age who had a diagnosis of essential hypertension within the first six months of the measurement period or any time prior to the measurement period	Patients with evidence of end stage renal disease (ESRD), dialysis or renal transplant before or during the measurement period. Also, exclude patients with a diagnosis of pregnancy during the measurement period. Exclude patients who were in hospice care during the measurement year	None
238	Use of High-Risk Medications in the Elderly	Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported. a. Percentage of patients who were ordered at least one high-risk medication. b. Percentage of patients who were ordered at least two different high-risk medications.	Patient Safety	Numerator 1: Patients with an order for at least one high-risk medication during the measurement period Numerator 2: Patients with at least two orders for the same high-risk medication during the measurement period	Patients 65 years and older who had a visit during the measurement period	Exclude patients who were in hospice care during the measurement year	None

QCDR and MIPS Measure Specifications

Measure ID	Measure Title	Measure Description	NQS Domain	Numerator	Denominator	Denominator Exclusions	Denominator Exceptions
462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy	Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT	Effective Clinical Care	Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment	Patients with a diagnosis of prostate cancer and who are actively undergoing ADT for a period greater than or equal to 12 months with an office visit during the measurement period	None	None